Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Surg. 2004 May;91(5):540-51.

Neoadjuvant therapy for oesophagogastric cancer.

Author information

1
Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, D-81675 Munich, Germany. f.lordick@lrz.tu-muenchen.de

Abstract

BACKGROUND:

The prognosis after surgery for oesophagogastric cancer remains poor.

METHODS:

This review clarifies current indications for neoadjuvant therapy for oesophageal and gastric cancer. A systematic literature research and evaluation of data from international cancer meetings were carried out.

RESULTS:

Recently published results of large randomized phase III trials underscore the potential value of neoadjuvant treatment for oesophagogastric cancer. However, it remains uncertain which subgroups of patients should routinely undergo preoperative therapy. Metabolic response evaluation during neoadjuvant treatment is a promising tool for the selection of responding patients.

CONCLUSION:

Neoadjuvant chemotherapy is a valid option for locally advanced oesophageal and gastric cancer. In the future, more effective and better tolerated treatment strategies, tailored to the specific tumour characteristics of each individual, should be possible.

PMID:
15122603
DOI:
10.1002/bjs.4575
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center